{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:33:36Z","timestamp":1789180416585,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Background and Objectives: Anemia is a common complication of chronic kidney disease (CKD) and is associated with reduced quality of life, accelerated disease progression, and increased cardiovascular risk. Sodium\u2013glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated significant renal and cardiovascular benefits, and clinical trials have reported improvements in hematologic parameters during treatment. However, real-world evidence regarding their longitudinal effects on hemoglobin (Hb) and iron metabolism in patients with CKD remains limited. Materials and Methods: We conducted a pre\u2013post analysis of 118 adult patients with CKD stages 1\u20134 treated with SGLT2is (empagliflozin or dapagliflozin) at the University Clinical Center of Serbia between January 2024 and June 2025. Patients received either agent at 10 mg once daily for 18 months. Hb, ferritin, C-reactive protein (CRP), albumin (Alb), daily proteinuria (Prt), and estimated glomerular filtration rate (eGFR) were assessed at baseline and at 18 months. Ferritin was adjusted for inflammatory and nutritional status using a residualization model incorporating CRP and Alb. Changes between the two time points were analyzed using repeated-measures general linear models (GLMs). Results: In unadjusted analyses, mean Hb increased modestly from 136.5 \u00b1 17.9 g\/L at baseline to 138.8 \u00b1 18.9 g\/L at follow-up (p = 0.028), while median ferritin decreased from 102.2 \u00b5g\/L to 89.9 \u00b5g\/L (p = 0.011). After adjustment for CRP and Alb, ferritin levels remained unchanged (p = 0.752). Repeated-measures analyses showed no significant longitudinal effect of time on Hb or ferritin and no significant interaction between time and SGLT2i type. Baseline eGFR, Prt, sex, and baseline ferritin significantly influenced longitudinal hematologic trajectories. Conclusions: SGLT2i therapy was associated with modest increases in Hb levels over 18 months, while inflammatory status remained stable and no significant reduction in ferritin levels was observed after adjustment for inflammatory and nutritional factors. Longitudinal Hb and ferritin trajectories did not differ significantly between empagliflozin and dapagliflozin, while baseline kidney function, Prt, iron status, and sex significantly influenced hematologic outcomes. Although causal inference is limited by the absence of a control group, these findings suggest a possible favorable effect of SGLT2is on anemia-related parameters in patients with CKD.<\/jats:p>","DOI":"10.3390\/medsci14020328","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:22:56Z","timestamp":1781684576000},"page":"328","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Sodium\u2013Glucose Cotransporter-2 Inhibitors on Anemia in Patients with Chronic Kidney Disease: A Pre\u2013Post Observational Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-261X","authenticated-orcid":false,"given":"Selena","family":"Gaji\u0107","sequence":"first","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Simovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bonti\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-7955","authenticated-orcid":false,"given":"Aleksandra","family":"Kezi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-6961","authenticated-orcid":false,"given":"Milorad","family":"Stojadinovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetozar","family":"Miju\u0161kovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Pavlovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3744-1819","authenticated-orcid":false,"given":"Vidna Karad\u017ei\u0107","family":"Ristanovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verica Stankovi\u0107","family":"Popovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Vi\u0107entijevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milija","family":"Bjeli\u010di\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6174-0932","authenticated-orcid":false,"given":"Ivana","family":"Mr\u0111a","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2763-5244","authenticated-orcid":false,"given":"Kristina","family":"Fili\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3446-4900","authenticated-orcid":false,"given":"Saddam","family":"Shawamri","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0890-535X","authenticated-orcid":false,"given":"Sanja","family":"Stankovi\u0107","sequence":"additional","affiliation":[{"name":"Center for Medical Biochemistry, University Clinical Center of Serbia, 11000 Belgrade, Serbia"},{"name":"Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5585-9793","authenticated-orcid":false,"given":"Marko","family":"Barali\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Badura, K., Janc, J., W\u0105sik, J., Gnitecki, S., Skwira, S., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2024). Anemia of Chronic Kidney Disease-A Narrative Review of Its Pathophysiology, Diagnosis, and Management. Biomedicines, 12.","DOI":"10.3390\/biomedicines12061191"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100677","DOI":"10.1016\/j.xkme.2023.100677","article-title":"Iron-Deficiency Anemia in CKD: A Narrative Review for the Kidney Care Team","volume":"5","author":"Hain","year":"2023","journal-title":"Kidney Med."},{"key":"ref_3","unstructured":"KDIGO Anemia Work Group (2012). KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl., 2, 279\u2013335."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s41100-024-00588-2","article-title":"Impact of anemia on renal outcomes in elderly patients with chronic kidney disease: A cohort study","volume":"10","author":"Mori","year":"2024","journal-title":"Ren. Replace. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pan, W., Han, Y., Hu, H., and He, Y. (2022). Association between hemoglobin and chronic kidney disease progression: A secondary analysis of a prospective cohort study in Japanese patients. BMC Nephrol., 23.","DOI":"10.1186\/s12882-022-02920-6"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hanke, J., Romejko, K., and Niemczyk, S. (2025). Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use\u2014Reviewing Protective Effects Exceeding Glycemic Control. Molecules, 30.","DOI":"10.3390\/molecules30204125"},{"key":"ref_7","unstructured":"Nuffield Department of Population Health Renal Studies Group, and SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4354892","DOI":"10.1155\/jcpt\/4354892","article-title":"SGLT2 Inhibitors Increase Hemoglobin and Hematocrit Levels in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"2025","author":"Choi","year":"2025","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.0000000000000362","article-title":"Alleviation of Anemia by SGLT2 Inhibitors in Patients with CKD: Mechanisms and Results of Long-Term Placebo-Controlled Trials","volume":"19","author":"Packer","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"xvag027","DOI":"10.1093\/eschf\/xvag027","article-title":"Effect of SGLT2 inhibitors on hemoglobin and hematocrit levels in Heart failure: A systematic review and meta-analysis","volume":"13","author":"Armani","year":"2026","journal-title":"ESC Heart Fail."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102702","DOI":"10.1016\/j.dsx.2022.102702","article-title":"Increase in hematocrit with SGLT-2 inhibitors\u2014Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?","volume":"17","author":"Ekanayake","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000531084","article-title":"Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia","volume":"55","author":"Milton","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jn\/nxz008","article-title":"Regression Correction Equation to Adjust Serum Iron and Ferritin Concentrations Based on C-Reactive Protein and Albumin in Patients Receiving Primary and Secondary Care","volume":"149","author":"McSorley","year":"2019","journal-title":"J. Nutr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2517086","DOI":"10.1001\/jamanetworkopen.2025.17086","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors, Erythrocytosis, and Thrombosis in Adults With Type 2 Diabetes","volume":"8","author":"Lewis","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_17","first-page":"165","article-title":"Effect of SGLT2 inhibitors on anemia and their possible clinical implications","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrologia Engl. Ed."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_19","first-page":"141","article-title":"The impact of SGLT2 inhibitors on hemoglobin levels in type 2 diabetes: Potential benefits beyond glycemic and renal outcomes","volume":"63","author":"Hoca","year":"2025","journal-title":"Med. Bull. Haseki."},{"key":"ref_20","first-page":"619","article-title":"Hypoxia-inducible factors in the kidney","volume":"17","author":"Haase","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in chronic kidney disease","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit increase by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_25","first-page":"717","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reconsideration of the role of erythropoietin","volume":"142","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.2147\/JMDH.S535423","article-title":"Determinants of Anemia Among Patients with Chronic Kidney Disease: A Systematic Review of Empirical Evidence","volume":"18","author":"Prapaiwong","year":"2025","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41100-025-00612-z","article-title":"Reconsideration of the anemia management strategy for chronic kidney disease and dialysis patients","volume":"11","author":"Daimon","year":"2025","journal-title":"Ren. Replace. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gluba-Brz\u00f3zka, A., Franczyk, B., Olszewski, R., and Rysz, J. (2020). The Influence of Inflammation on Anemia in CKD Patients. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030725"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3945\/jn.108.104026","article-title":"Adjusting for the acute phase response is essential to interpret iron status indicators among young Zanzibari children prone to chronic malaria and helminth infections","volume":"139","author":"Wright","year":"2009","journal-title":"J. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: Beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2013.12.003","article-title":"The sex difference in haemoglobin levels in adults","volume":"28","author":"Murphy","year":"2014","journal-title":"Blood Rev."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:17:31Z","timestamp":1781687851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/2\/328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medsci14020328"],"URL":"https:\/\/doi.org\/10.3390\/medsci14020328","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}